Modelling the topography of @entity154 in @entity1 exposed to the anti- XXXX drug @entity5305 and in normal subjects using automated static suprathreshold perimetry of the entire 80   visual field.

@entity1 @entity154 @entity227 @entity5305 @entity1582 @entity302
AIM: (i) To map the spatial distribution of absolute @entity227 ( @entity1582 ) in @entity1 exposed to @entity5305 and to compare the findings with @entity1582 in normal individuals, and (ii) to describe the relationship between the major risk factors for absolute loss (gender, age, cumulative dose), and the severity of field loss, expressed as the number of locations with @entity1582 per eye. METHODS: Visual field plots were retrospectively reviewed from 428 individuals. Perimetry was done with the T  bingen Automated Perimeter (using a threshold-oriented, marginally supraliminal strategy, 80   eccentricity, 99 test locations). Three hundred and sixty-one individuals were ophthalmologically normal, and 67 were @entity1 exposed to @entity5305 who had performed reliably during perimetry prior to neurosurgery for @entity302 . Two hundred and sixty-six of the 361 normals were included on the empirical basis that they manifested @entity1582 at no more than 19 stimulus locations per eye (the 74th percentile). The frequency per eye of @entity1582 at each of 99 stimulus locations was determined for the normals and @entity1 . The effects of age, gender and cumulative dose of @entity5305 on the number of ALs per individual was assessed by an analysis of covariance. A stochastic model was developed to determine the 50% probability of @entity1582 at each location. RESULTS: Thirty-nine of the 67 @entity5305 @entity1 exhibited at least 20 locations with @entity1582 . The number of ALs was independent of age (p    =    0.7603). The frequency of @entity1582 was 14.8% in the peripheral field and 1.0% in the central field (odds ratio 16.7; 95% CI 15.0-18.6%; p    <    0.0001). Those exposed to @entity5305 exhibited a frequency of 17.1% ALs, compared to 5.2% for the normal individuals (odds ratio 3.77, 95% CI 3.6-4.0%; p    <    0.0001). According to the modelled data, males exhibited 20.9% (95% CI 1.3-44%; p    =    0.0360) more absolute losses than did females. The number of absolute losses per @entity1 doubled with an increase in cumulative dose of @entity5305 of 936 g (95% CI 775-1181  g). CONCLUSIONS: According to this retrospective study, the spatial configuration of @entity154 attributable to @entity5305 indicates sparing of the temporal field up to approximately 60   eccentricity. Such a finding is likely to explain, at least in part, the initially asymptomatic nature of the defect. This study reconfirms a (cumulative) dose effect of @entity5305 on the extent of absolute field loss, with a greater risk for male gender.
